Stockreport

Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics [Seeking Alpha]

Bioventus Inc. - Class A  (BVS) 
PDF CEO Robert Claypoole highlighted that "Bioventus delivered another solid quarter and concluded a successful year across our strategic priorities while helping patients [Read more]